The unique ability of the Aquilion ONE to acquire the entire heart in a single temporally uniform volume permits quantitative myocardial perfusion analysis to be performed with the same data used for coronary CTA. A similar acquisition during pharmacological stress permits the comprehensive evaluation of the myocardial perfusion in ONE examination.
It is now possible to perform a comprehensive cardiac functional and morphological analysis in just one, low-dose examination using Toshiba’s Aquilion ONE. This technology can reduce the need to perform multiple examinations using different modalities, a true economical advantage and valuable contribution in cardiac healthcare.
CT Cardiac imaging, so far, is hampered from quantifying cardiac tissue functionality caused by obstructed coronaries and/or infarcts. In order to visualize the entire heart, other scanners need to move the patient causing undesired, time-delayed contrast distribution over the heart. The unique 16cm z-axis coverage of the Aquilion ONETM, allows scanning of the heart at a single moment in time resulting in temporal homogeneous contrast distribution.
Myocardial Perfusion is interpreted by comparing rest and stress data. The rest scan is usually performed using a low dose, prospective CT angiography protocol. Pending body mass index and heart-rate, sub-mSv protocols may be applied. After administration of a pharmacological stress agent, a low dose stress scan is performed.
Myocardial Perfusion
Key features:
Whole-heart acquisition in a single temporally uniform value.- Accurate diagnosis: Myocardial Perfusion combined with coronary CTA can accurately asses myocardial perfusion and identify the coronary arteries responsible for ischemia.
- Ultra-low dose: All required perfusion data can be obtained by just one scan.
CORE320 Multi-centre Trial
As the next phase in validating advanced cardiac computed tomography technology in a clinical setting, Toshiba Medical Systems is supporting CORE320, the worldwide multi-center trial comparing the effectiveness of 320-detector row dynamic volume CT to conventional angiography and SPECT technology. The trial aims to determine whether the combination of CT angiography and CT myocardial perfusion can identify coronary stenoses that are greater than or equal to 50 percent by Quantitative Coronary Analysis (QCA) and correspond to a SPECT perfusion defect.